SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Steg Philippe Gabriel) "

Sökning: WFRF:(Steg Philippe Gabriel)

  • Resultat 1-10 av 86
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bhatt, Deepak L., et al. (författare)
  • Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
  • 2019
  • Ingår i: ; 42:5, s. 498-505
  • Tidskriftsartikel (refereegranskat)abstract
    • In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients >= 50 years with type 2 diabetes receiving anti-diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of >= 50% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19 220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events are expected to be available for analysis, with an expected average follow-up of 40 months (maximum 58 months). Most of the exposure is on a 60 mg twice daily dose, as the dose was lowered from 90 mg twice daily partway into the study. The results may revise the boundaries of efficacy for dual antiplatelet therapy and whether it has a role outside acute coronary syndromes, prior myocardial infarction, or percutaneous coronary intervention.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Patrono, Carlo, et al. (författare)
  • Antiplatelet agents for the treatment and prevention of atherothrombosis
  • 2011
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 32:23, s. 2922-32
  • Forskningsöversikt (refereegranskat)abstract
    • The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Alexander, John H., et al. (författare)
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation : insights from the ARISTOTLE trial
  • 2014
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 35:4, s. 224-232
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims We assessed the effect of concomitant aspirin use on the efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation (AF). Methods and results In ARISTOTLE, 18 201 patients were randomized to apixaban 5 mg twice daily or warfarin. Concomitant aspirin use was left to the discretion of the treating physician. In this predefined analysis, simple and marginal structured models were used to adjust for baseline and time-dependent confounders associated with aspirin use. Outcome measures included stroke or systemic embolism, ischaemic stroke, myocardial infarction, mortality, major bleeding, haemorrhagic stroke, major or clinically relevant non-major bleeding, and any bleeding. On Day 1, 4434 (24%) patients were taking aspirin. Irrespective of concomitant aspirin use, apixaban reduced stroke or systemic embolism [with aspirin: apixaban 1.12% vs. warfarin 1.91, hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.39-0.85 vs. without aspirin: apixaban 1.11% vs. warfarin 1.32%, HR 0.84, 95% CI 0.66-1.07; P interaction = 0.10] and caused less major bleeding than warfarin (with aspirin: apixaban 3.10 vs. warfarin 3.92%, HR 0.77, 95% CI 0.60-0.99 vs. without aspirin: apixaban 1.82% vs. warfarin 2.78, HR without aspirin 0.65, 95% CI 0.55-0.78; P interaction = 0.29). Similar results were seen in the subgroups of patients with and without arterial vascular disease. Conclusion Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 86
  • [1]234567...9Nästa
Typ av publikation
tidskriftsartikel (84)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (80)
övrigt vetenskapligt (6)
Författare/redaktör
Steg, Philippe Gabri ... (84)
Cannon, Christopher ... (44)
Storey, Robert F. (34)
Wallentin, Lars, 194 ... (27)
Wallentin, Lars (27)
Himmelmann, Anders (26)
visa fler...
Harrington, Robert A ... (24)
Becker, Richard C. (23)
Husted, Steen (22)
Bhatt, Deepak L. (18)
Katus, Hugo A (15)
James, Stefan K (15)
Nordaby, Matias (14)
Hohnloser, Stefan H (14)
Lip, Gregory Y H (14)
ten Berg, Jurrien M. (14)
Budaj, Andrzej (13)
Granger, Christopher ... (12)
Held, Claes (12)
Held, Claes, 1956- (12)
Valgimigli, Marco (12)
Huber, Kurt (11)
Hagström, Emil (11)
James, Stefan K, 196 ... (11)
James, Stefan (11)
White, Harvey D. (10)
Miede, Corinna (10)
Lopes, Renato D. (9)
Oldgren, Jonas, 1964 ... (9)
Kimura, Takeshi (9)
Siegbahn, Agneta (8)
Windecker, Stephan (8)
James, Stefan, 1964- (8)
De Caterina, Raffael ... (8)
Siegbahn, Agneta, 19 ... (8)
Koenig, Wolfgang (8)
Collet, Jean-Philipp ... (7)
Armstrong, Paul W. (7)
Alexander, John H. (7)
Mahaffey, Kenneth W. (7)
Costa, Francesco (7)
Bueno, Héctor (6)
Montalescot, Gilles (6)
Varenhorst, Christop ... (6)
Katus, Hugo (6)
Ardissino, Diego (6)
Mauri, Laura (6)
Kastrati, Adnan (6)
Neumann, Franz-Josef (6)
Pieper, Karen S. (6)
visa färre...
Lärosäte
Uppsala universitet (79)
Göteborgs universitet (5)
Linnéuniversitetet (3)
Karolinska Institutet (2)
Lunds universitet (1)
Språk
Engelska (86)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (67)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy